Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
The Motley Fool April 21, 2011 Brian Orelli	Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool July 12, 2010 Ryan McBride	Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009.
The Motley Fool June 21, 2011 Alexander Crawford	Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list?
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool May 16, 2007 Brian Lawler	GPC's Next Cancer Drug? GPC Biotech prepares for its future as it awaits an FDA decision on its lead drug. Investors, take note.
BusinessWeek May 21, 2007 Gene G. Marcial	CombinatoRx Has A Rich Pipeline Even though CombinatoRx is tiny, the institutional big guns own stock.
The Motley Fool December 19, 2011 Brian Orelli	ARIAD's Prolific 2011 The biotech is doing something right.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool February 17, 2011 Brian Orelli	Nice Deal, Now Let's See Some Data AVEO Pharmaceuticals struck a solid partnership with Astellas Pharma and its investors are rewarding the company today.
The Motley Fool March 21, 2011 Brian Orelli	Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug.
BusinessWeek August 7, 2006 Gene G. Marcial	Emisphere Dances With Giants Tiny biotech Emisphere Technologies has attracted Big Pharma to team up on its products still in clinical trials.
The Motley Fool November 19, 2010 Brian Orelli	Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all.
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.
The Motley Fool April 27, 2011 Brian Orelli	Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool May 2, 2011 Brian Orelli	Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror.
The Motley Fool May 19, 2010 Brian Orelli	The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd.
The Motley Fool July 6, 2009 Brian Orelli	Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer.
The Motley Fool October 9, 2006 Brian Lawler	The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field.
The Motley Fool November 3, 2011 Sean Williams	Bash My Stock: Ariad Pharmaceuticals For those of you who've wondered what's wrong with your stock...
The Motley Fool December 23, 2011 Selena Maranjian	3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick.
The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
The Motley Fool May 2, 2011 Tim Beyers	Spectrum Pharmaceuticals Shares Popped: What You Need to Know Shares of Spectrum Pharmaceuticals rose as much as 14% in intraday trading after the Food and Drug Administration approved Fusilev as a colon cancer treatment.
The Motley Fool November 2, 2004 Charly Travers	Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer.
The Motley Fool October 31, 2006 Brian Lawler	A Look Inside the Biotech Haunted House Even after being warned of the risks, if you're still brave enough to come inside the biotech haunted house, realize that there are surprises. For example, the FDA will spook investors with calls for more clinical trials on drugs that appear to be a lock for approval.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
The Motley Fool July 27, 2010 Jim Mueller	3 Stocks to Play Biotech Here are three promising ideas for this exciting area.
BusinessWeek November 3, 2003	Spectrum's New Cancer Weapons Several big investors have been buying little-known Spectrum Pharmaceuticals, which develops anticancer agents that have previous clinical data to back their efficacy and safety.
The Motley Fool October 14, 2011 Sean Williams	7 FDA Decisions You Can't Afford to Ignore in Q4 These stocks are bound to move as the FDA weighs in on their prospective drugs in Q4: Bristol-Myers... BioSante... Teva... Regeneron... Transcept... Incyte... Antares Pharma...
The Motley Fool January 2, 2012 Sean Williams	2012 Preview: Aeterna Zentaris Let's look ahead and see what will be driving Aeterna's stock price in 2012.
The Motley Fool August 15, 2011 Jim Royal	6 Wild Bets on Biotech Riches The most interesting biotech tickers.
The Motley Fool November 20, 2007 Brian Orelli	Explaining Onyx Pharmaceuticals' Sell-Off The FDA approved Nexavar as a treatment for liver cancer, but the good news causes a sell-off of the stock.
The Motley Fool May 10, 2005 Charly Travers	The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice?
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.
The Motley Fool January 12, 2005 Charly Travers	Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise.
The Motley Fool April 14, 2011 Brian Orelli	Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year.
BusinessWeek June 4, 2007 Gene G. Marcial	Amgen Believers There has been a deluge of bad news at biotech Amgen, whose stock has tumbled.
The Motley Fool July 28, 2010 Jordan DiPietro	3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage
Investment Advisor December 2005 Greg B. Scott	Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.
The Motley Fool February 26, 2010 Brian Orelli	A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus.
The Motley Fool March 16, 2011 Brian Orelli	Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.
The Motley Fool September 3, 2004 Charly Travers	MGI Pharma's Shopping Spree The company is filling out its drug pipeline with acquisitions.
The Motley Fool November 26, 2010 Brian Orelli	Black Friday Biotech Bargains Drugmakers on sale.
The Motley Fool June 9, 2010 Brian Orelli	ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology.
The Motley Fool April 3, 2009 Brian Orelli	Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately.
The Motley Fool June 6, 2006 Brian Lawler	Exelixis' Continued Excellence The company reported preliminary phase 1 results for three of its lead compounds. Until investors see the results from phase 2 trials, they should chalk Exelixis up as a promising young biotech company whose successes they will patiently cheer for from the sidelines.